Literature DB >> 22927059

Testosterone replacement therapy and prostate health.

A Scott Polackwich1, Kevin A Ostrowski, Jason C Hedges.   

Abstract

There is an emerging evolution in the understanding of the relationship between the prostate and testosterone. It has long been generally believed that with testosterone replacement therapy (TRT), increasing serum testosterone levels led to prostatic growth and worsening of voiding dysfunction and associated complications. A new theory, the Saturation Model of Testosterone and its effect on the Prostate has gained attention. This theory suggests that the prostate's response to increasing levels of serum testosterone reaches a limit beyond which there is minimal effect. This model predicts that testosterone replacement therapy occurs above this saturation point, and replacing testosterone to eugonadal levels should not worsen prostate related benign disease. We evaluated the recent published data, with an emphasis on clinical studies done within the last 3 years, for the effects of testosterone supplementation on benign prostatic disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22927059     DOI: 10.1007/s11934-012-0275-8

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  33 in total

Review 1.  A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors:  Mauro Gacci; Giovanni Corona; Matteo Salvi; Linda Vignozzi; Kevin T McVary; Steven A Kaplan; Claus G Roehrborn; Sergio Serni; Vincenzo Mirone; Marco Carini; Mario Maggi
Journal:  Eur Urol       Date:  2012-02-25       Impact factor: 20.096

2.  Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.

Authors:  Christina Wang; Glenn Cunningham; Adrian Dobs; Ali Iranmanesh; Alvin M Matsumoto; Peter J Snyder; Thomas Weber; Nancy Berman; Laura Hull; Ronald S Swerdloff
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

3.  Androgen deprivation induces bladder histological abnormalities and dysfunction via TGF-β in orchiectomized mature rats.

Authors:  Yong Zhang; Jimin Chen; Linyi Hu; Zhaodian Chen
Journal:  Tohoku J Exp Med       Date:  2012-02       Impact factor: 1.848

4.  Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.

Authors:  Michael Marberger; Claus G Roehrborn; Leonard S Marks; Timothy Wilson; Roger S Rittmaster
Journal:  J Clin Endocrinol Metab       Date:  2006-01-24       Impact factor: 5.958

5.  Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.

Authors:  S M Harman; E J Metter; J D Tobin; J Pearson; M R Blackman
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

6.  Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.

Authors:  Stephanie T Page; Lianne Hirano; Janet Gilchriest; Manjiri Dighe; John K Amory; Brett T Marck; Alvin M Matsumoto
Journal:  J Urol       Date:  2011-05-14       Impact factor: 7.450

7.  Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial.

Authors:  Stephanie T Page; Daniel W Lin; Elahe A Mostaghel; Brett T Marck; Jonathan L Wright; Jennifer Wu; John K Amory; Peter S Nelson; Alvin M Matsumoto
Journal:  J Clin Endocrinol Metab       Date:  2010-12-22       Impact factor: 5.958

8.  Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.

Authors:  Mohit Khera; Rajib K Bhattacharya; Gary Blick; Harvey Kushner; Dat Nguyen; Martin M Miner
Journal:  J Urol       Date:  2011-07-23       Impact factor: 7.450

9.  Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia.

Authors:  Sung Kyu Hong; Gyeong Eun Min; Seung Bum Ha; Seung Hwan Doo; Min Yong Kang; Hong Joo Park; Cheol Yong Yoon; Seong Jin Jeong; Seok-Soo Byun; Sang Eun Lee
Journal:  BJU Int       Date:  2009-09-29       Impact factor: 5.588

10.  Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.

Authors:  Robert M Coward; Jay Simhan; Culley C Carson
Journal:  BJU Int       Date:  2008-12-23       Impact factor: 5.588

View more
  1 in total

Review 1.  Benefits and Consequences of Testosterone Replacement Therapy: A Review.

Authors:  Polackwich As; Tadros Nn; Ostrowski Ka; Hedges Jc
Journal:  Eur Endocrinol       Date:  2013-03-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.